Takeda Pharmaceutical Company Limited: Takeda Receives Positive CHMP Opinion Recommending Approval of Dengue Vaccine Candidate in EU and Dengue-Endemic Countries

TAK-003 Recommended for the Prevention of Dengue Disease Caused by Any Dengue Virus Serotype in Individuals Four Years of Age and Older in the EU and in Dengue-Endemic Countries Participating in

Related Keywords

Indonesia ,Sri Lanka ,Japan ,Philippines ,United States ,Brazil ,Colombia ,Nicaragua ,Germany ,Thailand ,Siyambalapitiya ,Sabaragamuwa ,Dominican Republic ,Singapore ,Bulugahapitiya ,Central ,Italy ,Panama ,Spain ,France ,Ibadan ,Jawa Tengah ,America ,Japanese ,Gary Dubin ,Eng Eong ,South East Asia ,Rachel Higgins ,Jun Saito ,Centers For Disease ,World Health Organization ,International Media ,Data Monitoring Committee ,Indonesia National Agency For Drug ,Exchange Commission ,Takeda Pharmaceutical Company Limited ,European Medicines Agency ,European Centre For Disease Prevention ,Natural Resources Defense Council ,Committee For Medicinal Products Human Use ,Dengue Disease Caused ,Any Dengue Virus Serotype ,Individuals Four Years ,Dengue Endemic Countries Participating ,Efficacy Data ,Pivotal Phase ,Adolescents Across Eight Dengue Endemic ,Authorization Expected ,Coming Months ,Europe Followed ,Regulatory Decisions ,Latin America ,Medicinal Products ,Human Use ,Marketing Authorization ,Global Vaccine Business Unit ,Western Pacific ,Ooi Eng Eong ,Emerging Infectious Diseases ,Dengue Efficacy Study ,Dengue Tetravalent Vaccine ,Indonesia National Agency ,Food Control ,Fiscal Year ,Rare Genetics ,Plasma Derived Therapies ,Annual Report ,Borne Dengue Fever Threat Spreading ,Disease Control ,Dengue For Healthcare Providers Clinical ,Disease Prevention ,Report Series ,European Medicines ,Tetravalent Dengue Vaccine ,Healthy Children ,Retrieved August ,Takeda ,Harmaceutical ,Company ,Imited ,Eceives ,Positive ,Thmp ,Opinion ,Recommending ,Approval ,Dengue ,Vaccine ,Candidate ,Pandemic ,Countries ,